Cell Signaling Technology

Acetyl-Histone H3 (Lys56) Antibody

#4243 · $150

100
Citing papers
10.7k
Combined citations
Supplier page Find this product

Research areas

Cancer-related gene regulation10Epigenetics and DNA Methylation9Chronic Myeloid Leukemia Treatments6Cancer-related molecular mechanisms research6Cancer Cells and Metastasis5RNA modifications and cancer5Endoplasmic Reticulum Stress and Disease5Cell Adhesion Molecules Research4

Papers citing this product

1
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
The EMBO Journal·2012·772 cit.·DOI
2
Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury
American Journal Of Pathology·2007·709 cit.·DOI
3
CX3CR1 Deficiency Leads to Impairment of Hippocampal Cognitive Function and Synaptic Plasticity
Journal of Neuroscience·2011·628 cit.·DOI
4
Implications of the tumor immune microenvironment for staging and therapeutics
Modern Pathology·2017·364 cit.·DOI
5
Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis
Cell Metabolism·2023·329 cit.·DOI
6
Paracrine and Autocrine Functions of Neuronal Vascular Endothelial Growth Factor (VEGF) in the Central Nervous System
Journal of Biological Chemistry·2002·271 cit.·DOI
7
Isoflurane Protects against Myocardial Infarction during Early Reperfusion by Activation of Phosphatidylinositol-3-Kinase Signal Transduction: Evidence for Anesthetic-induced Postconditioning in Rabbits
Anesthesiology·2004·252 cit.·DOI
8
HSP72 Protects Cells from ER Stress-induced Apoptosis via Enhancement of IRE1α-XBP1 Signaling through a Physical Interaction
PLoS Biology·2010·238 cit.·DOI
9
Luteinizing Hormone Signaling in Preovulatory Follicles Involves Early Activation of the Epidermal Growth Factor Receptor Pathway
Molecular Endocrinology·2008·208 cit.·DOI
10
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
Blood·2004·198 cit.·DOI